Stockscreener 앱 받기
28.54
1.89%
-0.55
시간 외 거래:
28.43
-0.11
-0.39%
전일 마감가:
$29.09
열려 있는:
$29.06
하루 거래량:
116.33K
Relative Volume:
0.80
시가총액:
$961.72M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+4.54%
1개월 성능:
+7.13%
6개월 성능:
+30.32%
1년 성능:
+32.44%
1일 변동 폭
$28.34
$29.71
1주일 범위
$26.79
$29.71
52주 변동 폭
$14.35
$36.37
Arrivent Biopharma Inc Stock (AVBP) Company Profile
명칭
Arrivent Biopharma Inc
전화
240-780-6356
주소
18 CAMPUS BLVD., NEWTOWN SQUARE
AVBP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
28.54 | 961.72M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-22 | 개시 | Oppenheimer | Outperform |
| 2024-04-30 | 개시 | H.C. Wainwright | Buy |
| 2024-02-20 | 개시 | Citigroup | Buy |
| 2024-02-20 | 개시 | Goldman | Buy |
| 2024-02-20 | 개시 | Jefferies | Buy |
Arrivent Biopharma Inc 주식(AVBP)의 최신 뉴스
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Shares Bought by JPMorgan Chase & Co. - Defense World
(AVBP) Trading Signals - Stock Traders Daily
ArriVent in Newtown Square Sees Big Potential in New Cancer Drug - DELCO.Today
Abbvie seeks molecular glue degraders from Neomorph - BioCentury
ArriVent BioPharma Secures Global Rights to MRG007 in Strategic Deal with Lepu Biopharma - MSN
Equities Analysts Set Expectations for AVBP Q1 Earnings - Defense World
HC Wainwright Issues Positive Estimate for AVBP Earnings - MarketBeat
More China ADCs: Arrivent gets GI cancer drug in $1.2B Lepu deal - BioWorld Online
ArriVent Biopharma price target raised to $39 from $36 at H.C. Wainwright - Yahoo Finance
ArriVent Biopharma enters license agreement with Lepu Biopharma - MSN
Cancer Biotech ArriVent Lands an ADC for GI Malignancies and Makes Best-in-Class Claim - MedCity News
Intellia makes progress on HAE study; 2 more China drug deals - BioPharma Dive
ArriVent inks ADC licensing deal with Lepu Biopharma - The Pharma Letter
ArriVent bets big on experimental cancer drug with potential $1B licensing deal - The Business Journals
Arrivent Biopharma licenses ex-China rights to Lepu’s ADC for gastrointestinal cancers - BioWorld Online
ArriVent Joins Chinese Licensing Trend With Potential $1.2B+ ADC Deal with Lepu - BioSpace
ArriVent BioPharma (NASDAQ:AVBP) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Lepu Biopharma has granted ArriVent Exclusive License for MRG007, a Potential Best-in-Class ADC for the - Digital More
Lepu Biopharma has granted ArriVent Exclusive License for MRG007, a Potential Best-in-Class ADC for the treatment of Gastrointestinal Cancers - The Manila Times
Lepu Biopharma Co., Ltd. Enters into an Exclusive Licensing Agreement with Arrivent Biopharma, Inc - Marketscreener.com
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma - WICZ
Lepu Biopharma Grants Exclusive License for Novel ADC MRG007 to ArriVent - TipRanks
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers - The Manila Times
ArriVent BioPharma Secures Global Rights to Promising Cancer Drug MRG007 in $1.2B Deal - StockTitan
(AVBP) Investment Analysis - Stock Traders Daily
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Up 13.1% in December - MarketBeat
Windtree Therapeutics Secures Patent in Japan for Cancer Treatment Platform - MyChesCo
ArriVent BioPharma (NASDAQ:AVBP) Shares Gap DownWhat's Next? - MarketBeat
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Barclays PLC Has $976,000 Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Biopharma IPOs rebound slightly, as class of 2024 lags with a 29% average decline - BioWorld Online
Jane Street Group LLC Has $250,000 Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
We're Not Very Worried About ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Rate - Simply Wall St
ArriVent BioPharma (NASDAQ:AVBP) Trading Down 5%Should You Sell? - MarketBeat
Geode Capital Management LLC Increases Stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Barclays PLC Increases Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Stock Position Increased by Geode Capital Management LLC - MarketBeat
Barclays PLC Buys 38,132 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - MarketBeat
(AVBP) Proactive Strategies - Stock Traders Daily
State Street Corp Acquires 323,186 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - MarketBeat
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Stake Lifted by State Street Corp - Defense World
(AVBP) Pivots Trading Plans and Risk Controls - Stock Traders Daily
The Manufacturers Life Insurance Company Purchases Shares of 10,234 ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Up 6.1% in November - MarketBeat
Charles Schwab Investment Management Inc. Buys 122,641 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
BNP Paribas Financial Markets Raises Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Shares Acquired by Charles Schwab Investment Management Inc. - MarketBeat
Fmr LLC Purchases 169,514 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - MarketBeat
Suvretta Capital Management, LLC Acquires Additional Shares in A - GuruFocus.com
Short Interest in ArriVent BioPharma, Inc. (NASDAQ:AVBP) Decreases By 11.9% - MarketBeat
Suvretta Capital Management LLC Purchases 132,459 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - MarketBeat
Arrivent Biopharma Inc (AVBP) 재무 분석
Arrivent Biopharma Inc (AVBP)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
3.95%
2.39%
자본화:
|
볼륨(24시간):